New triple therapy targets hard-to-treat lung cancer before surgery
Disease control
Recruiting now
This study tests a new approach for people with a certain genetic lung cancer (KRAS G12C mutation) that can be removed with surgery. Before surgery, patients receive a targeted pill (fulzerasib) for 6 weeks, then a 2-week break, followed by 3 cycles of immunotherapy (sintilimab) …
Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control
Last updated May 11, 2026 20:51 UTC